Skip to content

Assessment of Potential Efficacy and Safety of Xianfang Huoming Decoction in Combination with ß-Lactam Antibiotics for the Treatment of Liver Abscess: A Multicenter, Prospective Cohort Study

Assessment of Potential Efficacy and Safety of Xianfang Huoming Decoction in Combination with ß-Lactam Antibiotics for the Treatment of Liver Abscess: A Multicenter, Prospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001233
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-05-20
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver abscess

Interventions

Xianfang Huoming Yin Treatment Group:Xianfang Huoming Yin combined with ß-lactam antibiotics and percutaneous catheter drainage.
Standardized Treatment Control Group:ß-lactam antibiotics + needle catheter drainage

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Adult patients aged between 18 and 80 years; patients presenting with characteristic clinical manifestations of liver abscess, such as chills, high fever, liver region pain, fatigue, loss of appetite, etc.; imaging examinations (ultrasound (US), computed tomography (CT), or magnetic resonance imaging (MRI)) showing characteristic features of liver abscess; pus extraction via aspiration or surgery, confirmed by bacterial culture results; exclusion of amebic liver abscess, tuberculous liver abscess, and liver abscess after liver transplantation; willingness to participate in the study with informed consent. The process of obtaining informed consent should comply with Good Clinical Practice (GCP) regulations.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1) Liver abscesses caused by amebic, tuberculosis, fungi, or other microorganisms, as well as liver abscesses caused by trauma; 2) Age 80 years; 3) Pregnancy or breastfeeding; 4) History of allergy to pus-scattering agents; 5) Unable to obtain informed consent or patients who do not agree; 6) Patients who are not actively participating in comprehensive and aggressive treatment.

Design outcomes

Primary

MeasureTime frame
The time for the abscess cavity to reduce by 30% or achieve complete absorption.;

Secondary

MeasureTime frame
Time of fever subsiding;Time of relief from abdominal pain;Procalcitonin;C-reactive protein;The normal time of inflammatory factors.;Pus bacterial culture;Stool bacterial culture;

Countries

China

Contacts

Public ContactLi Jiabin

The First Affiliated Hospital of Anhui Medical University

lijiabin@ahmu.edu.cn+8618956018570

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026